Impaired HDL anti-inflammatory activity in diabetes
Increasingly it is thought that the functionality of high-density lipoprotein (HDL) may have a pathophysiologically important impact in delaying the progression of atherosclerosis. This study shows that anti-inflammatory properties of HDLs are impaired in type 2 diabetes mellitus (T2DM) patients, even those with generally acceptable metabolic control. The study included 40 subjects with T2DM (median duration 5 years), none of whom were treated with insulin or statin, and 36 non-diabetic subjects. HDL anti-inflammatory capacity was determined as the ability to suppress tumor necrosis factor-? (TNF-?) induced vascular cell adhesion molecule-1 (VCAM-1) mRNA expression in endothelial cells in vitro, thus reflecting a critical early event in atherogenesis, i.e. the recruitment of macrophages into developing atherosclerotic lesions. T2DM was associated with impaired HDL anti-inflammatory capacity (by more than 3-fold in the test system), as well as decreased paraoxonase-1 activity, and enhanced low grade chronic inflammation. This impaired functionality of HDL may contribute to the increase in risk of atherosclerotic cardiovascular disease associated with T2DM.
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol 2017;16:132.
Ebtehaj S, Gruppen EG, Parvizi M et al.